Skip to main content

Advertisement

SpringerLink
Log in

Changing Incidence of Orthopedic Surgery in Rheumatic Disease: Contributing Factors

  • SURGERY AND PERIOPERATIVE CARE (CR MACKENZIE AND SM GOODMAN, SECTION EDITORS)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Rheumatic diseases are multisystem conditions that predominantly affect the musculoskeletal system, leading to soft tissue and articular damage. Historically, medical therapy was able to slow, but not prevent, erosion and joint destruction, resulting in the frequent need for orthopedic procedures to maintain function and minimize pain. However, the widespread use of disease-modifying anti-rheumatic drugs (DMARDs) and biologic therapy over the last twenty years has resulted in a dramatic decrease in the incidence of musculoskeletal damage and impairment among these patients. This review will discuss changing patterns of orthopedic surgery among patients with rheumatic diseases, focusing on rheumatoid arthritis and systemic lupus erythematosus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25.

    Article  PubMed  Google Scholar 

  2. Weiss RJ, Ehlin A, Montgomery SM, Wick MC, Stark A, Wretenberg P. Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology (Oxford). 2008;47:491–4.

    Article  CAS  Google Scholar 

  3. Dafydd M, Whitaker IS, Murison MS, Boyce DE. Change in operative workload for rheumatoid disease of the hand: 1,109 procedures over 13 years. J Plast Reconstr Aesthet Surg. 2012;65:800–3.

    Article  CAS  PubMed  Google Scholar 

  4. Weiss RJ, Stark A, Wick MC, Ehlin A, Palmblad K, Wretenberg P. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis. 2006;65:335–41.

    Article  CAS  PubMed  Google Scholar 

  5. Fevang BT, Lie SA, Havelin LI, Engesaeter LB, Furnes O. Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway, 1994–2004. Arthritis Rheum. 2007;57:529–32.

    Article  CAS  PubMed  Google Scholar 

  6. Shourt CA, Crowson CS, Gabriel SE, Matteson EL. Orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol. 2012;39:481–5. This shows a decrease in the incidence of soft tissue procedures in the first decade after RA diagnosis among an RA cohort in Olmsted County, Minnesota.

    Article  PubMed  Google Scholar 

  7. da Silva E, Doran MF, Crowson CS, O’Fallon WM, Matteson EL. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum. 2003;49:216–20.

    Article  PubMed  Google Scholar 

  8. Momohara S, Ikari K, Mochizuki T, et al. Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2009;68:291–2.

    Article  CAS  PubMed  Google Scholar 

  9. Gay DM, Lyman S, Do H, Hotchkiss RN, Marx RG, Daluiski A. Indications and reoperation rates for total elbow arthroplasty: an analysis of trends in New York State. J Bone Joint Surg Am. 2012;94:110–7.

    Article  PubMed  Google Scholar 

  10. Fevang BT, Lie SA, Havelin LI, Skredderstuen A, Furnes O. Results after 562 total elbow replacements: a report from the Norwegian Arthroplasty Register. J Shoulder Elbow Surg. 2009;18:449–56.

    Article  PubMed  Google Scholar 

  11. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1072–82.

    Article  CAS  PubMed  Google Scholar 

  12. Ward MM. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983–2001. Arthritis Rheum. 2004;50:1122–31.

    Article  PubMed  Google Scholar 

  13. Pedersen AB, Johnsen SP, Overgaard S, Soballe K, Sorensen HT, Lucht U. Total hip arthroplasty in Denmark: incidence of primary operations and revisions during 1996–2002 and estimated future demands. Acta Orthop. 2005;76:182–9.

    Article  PubMed  Google Scholar 

  14. Hekmat K, Jacobsson L, Nilsson JA, et al. Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis--results from a well defined population in south Sweden. Arthritis Res Ther. 2011;13:R67. This shows a decrease in the incidence of THA among patients with RA in Sweden.

    Article  PubMed  Google Scholar 

  15. Skytta ET, Honkanen PB, Eskelinen A, Huhtala H, Remes V. Fewer and older patients with rheumatoid arthritis need total knee replacement. Scand J Rheumatol. 2012;41:345–9. Using data from the Finnish Arthroplasty Register, this shows a decrease in the incidence of TKA among patients with RA in Finland.

    Article  CAS  PubMed  Google Scholar 

  16. Losina E, Thornhill TS, Rome BN, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am. 2012;94:201–7. This discusses reasons for the increase in TKA in the USA.

    Article  PubMed  Google Scholar 

  17. Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467:2606–12.

    Article  PubMed  Google Scholar 

  18. Ravi B, Croxford R, Reichmann WM, Losina E, Katz JN, Hawker GA. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26:637–47. This presents data on the increasing frequency of TKA and THA in the USA and Ontario and the changing demographics of these arthroplasty recipients.

    Article  PubMed  Google Scholar 

  19. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780–5.

    Article  PubMed  Google Scholar 

  20. United States National Library of Medicine: LiverTox: Methotrexate. Available at http://livertox.nlm.nih.gov/Methotrexate.htm. Accessed March 2013.

  21. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum. 1991;34:961–72.

    Article  CAS  PubMed  Google Scholar 

  22. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994;37:1492–8.

    Article  CAS  PubMed  Google Scholar 

  23. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–7.

    Article  CAS  PubMed  Google Scholar 

  24. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.

    Article  CAS  PubMed  Google Scholar 

  25. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.

    Article  CAS  PubMed  Google Scholar 

  26. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.

    Article  PubMed  Google Scholar 

  27. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.

    Article  CAS  PubMed  Google Scholar 

  28. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.

    Article  PubMed  Google Scholar 

  29. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.

    Article  CAS  PubMed  Google Scholar 

  30. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.

    Article  CAS  PubMed  Google Scholar 

  31. Lipsky PE, van der Heijde DM. St Clair EW, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.

    Article  CAS  PubMed  Google Scholar 

  32. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.

    Article  CAS  PubMed  Google Scholar 

  33. Keystone E, Heijde D, Mason Jr D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319–29.

    Article  CAS  PubMed  Google Scholar 

  34. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68:797–804.

    Article  CAS  PubMed  Google Scholar 

  35. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805–11.

    Article  CAS  PubMed  Google Scholar 

  36. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83.

    Article  CAS  PubMed  Google Scholar 

  37. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–96.

    Article  CAS  PubMed  Google Scholar 

  38. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210–21.

    Article  CAS  PubMed  Google Scholar 

  39. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23.

    Article  CAS  PubMed  Google Scholar 

  40. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.

    Article  CAS  PubMed  Google Scholar 

  41. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062–8.

    Article  CAS  PubMed  Google Scholar 

  42. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 2003;48:927–34.

    Article  CAS  PubMed  Google Scholar 

  43. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–81.

    Article  CAS  PubMed  Google Scholar 

  44. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–400.

    Article  CAS  PubMed  Google Scholar 

  45. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806.

    Article  CAS  PubMed  Google Scholar 

  46. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.

    Article  CAS  PubMed  Google Scholar 

  47. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.

    Article  CAS  PubMed  Google Scholar 

  48. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.

    Article  CAS  PubMed  Google Scholar 

  49. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.

    Article  CAS  PubMed  Google Scholar 

  50. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.

    Article  PubMed  Google Scholar 

  51. Pincus T, Sokka T, Chung CP, Cawkwell G. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis. 2006;65:878–83.

    Article  CAS  PubMed  Google Scholar 

  52. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52:1009–19.

    Article  PubMed  Google Scholar 

  53. Chung KC, Pushman AG. Current concepts in the management of the rheumatoid hand. J Hand Surg Am. 2011;36:736–47.

    Article  PubMed  Google Scholar 

  54. Kolling C, Herren DB, Simmen BR, Goldhahn J. Changes in surgical intervention patterns in rheumatoid arthritis over 10 years in one centre. Ann Rheum Dis. 2009;68:1372–3.

    Article  CAS  PubMed  Google Scholar 

  55. Jacobsson LT, Hanson RL, Knowler WC, et al. Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum. 1994;37:1158–65.

    Article  CAS  PubMed  Google Scholar 

  56. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987–1989. Arthritis Rheum. 1991;34:1502–7.

    Article  CAS  PubMed  Google Scholar 

  57. Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46:625–31.

    Article  PubMed  Google Scholar 

  58. Hochberg MC. Changes in the incidence and prevalence of rheumatoid arthritis in England and Wales, 1970–1982. Semin Arthritis Rheum. 1990;19:294–302.

    Article  CAS  PubMed  Google Scholar 

  59. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–99.

    Article  CAS  PubMed  Google Scholar 

  60. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum. 2005;52:2616–24.

    Article  PubMed  Google Scholar 

  61. Mertelsmann-Voss C, Pan TJ, Lyman SL, Figgie MP, Mandl LA. Trends in US arthroplasty rates 1991–2005: patients with inflammatory arthritis continue to require joint replacement. Arthritis Rheum. 2012;64:S1122.

    Google Scholar 

  62. Hartz AJ, Fischer ME, Bril G, et al. The association of obesity with joint pain and osteoarthritis in the HANES data. J Chronic Dis. 1986;39:311–9.

    Article  CAS  PubMed  Google Scholar 

  63. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988;109:18–24.

    Article  CAS  PubMed  Google Scholar 

  64. Karlson EW, Mandl LA, Aweh GN, Sangha O, Liang MH, Grodstein F. Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am J Med. 2003;114:93–8.

    Article  PubMed  Google Scholar 

  65. Wolfe F, Michaud K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:1471–9.

    Article  Google Scholar 

  66. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165:1624–9.

    Article  PubMed  Google Scholar 

  67. Robinson WR, Utz RL, Keyes KM, Martin CL, Yang Y: Birth cohort effects on abdominal obesity in the United States: the Silent Generation, Baby Boomers and Generation X. Int J Obes (Lond) 2012. [Epub ahead of print]

  68. Business Wire: Baby boomers expect to beat the odds with more active, longer lives; Rehabilitation Institute of Chicago releases survey of baby boomers’ outlook on aging, activity and healthcare. Available at http://www.businesswire.com/news/home/20031223005029/en/Baby-Boomers-Expect-Beat-Odds-Active-Longer. Accessed March 2013.

  69. Jennings F, Lambert E, Fredericson M. Rheumatic diseases presenting as sports-related injuries. Sports Med. 2008;38:917–30.

    Article  PubMed  Google Scholar 

  70. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, Schoones J, Van den Ende EC: Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev. 2009:CD006853.

  71. Jari S, Noble J. Meniscal tearing and rheumatoid arthritis. Knee. 2001;8:157–8.

    Article  CAS  PubMed  Google Scholar 

  72. Murray MM. Current status and potential of primary ACL repair. Clin Sports Med. 2009;28:51–61.

    Article  PubMed  Google Scholar 

  73. Lohmander LS, Ostenberg A, Englund M, Roos H. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum. 2004;50:3145–52.

    Article  CAS  PubMed  Google Scholar 

  74. Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35:1756–69.

    Article  PubMed  Google Scholar 

  75. von Porat A, Roos EM, Roos H. High prevalence of osteoarthritis 14 years after an anterior cruciate ligament tear in male soccer players: a study of radiographic and patient relevant outcomes. Ann Rheum Dis. 2004;63:269–73.

    Article  Google Scholar 

  76. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.

    Article  CAS  PubMed  Google Scholar 

  77. Mourao AF, Amaral M, Caetano-Lopes J, Isenberg D. An analysis of joint replacement in patients with systemic lupus erythematosus. Lupus. 2009;18:1298–302.

    Article  CAS  PubMed  Google Scholar 

  78. Mertelsmann-Voss C, Pan TJ, Do H, Figgie MP, Mandl LA. Arthoplasty rates increased among US patients with systemic lupus erythematosus: 1991–2005. Arthritis Rheum. 2012;64:S1088.

    Google Scholar 

  79. Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine. 1954;33:291–437.

    Article  CAS  PubMed  Google Scholar 

  80. Dubois EL, Wierzchowiecki M, Cox MB, Weiner JM. Duration and death in systemic lupus erythematosus. An analysis of 249 cases. JAMA. 1974;227:1399–402.

    Article  CAS  PubMed  Google Scholar 

  81. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol. 2008;26:S72–9.

    CAS  PubMed  Google Scholar 

  82. Jordan JM, Renner JB, et al. Self-reported functional status in osteoarthritis of the knee in a rural southern community: the role of sociodemographic factors, obesity, and knee pain. Arthritis Care Res (Hoboken). 1996;9:273–8.

    Article  CAS  Google Scholar 

  83. Shah U, Mandl LA, Figgie MP, Alexiades M, Goodman SM. Pain and Function Outcomes in Systemic Lupus Erythematosus Hip and Knee Arthroplasty. Arthritis Rheum. 2012;64:S1029.

    Google Scholar 

  84. Katz P, Gregorich S, Yazdany J, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63:261–8.

    Article  Google Scholar 

  85. Dwosh IL, Resnick D, Becker MA. Hip involvement in ankylosing spondylitis. Arthritis Rheum. 1976;19:683–92.

    Article  CAS  PubMed  Google Scholar 

  86. Vander Cruyssen B, Munoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford). 2010;49:73–81.

    Article  Google Scholar 

  87. Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis Jr JC. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis. 2008;67:233–7.

    Article  CAS  PubMed  Google Scholar 

  88. Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.

    CAS  PubMed  Google Scholar 

  89. Michet CJ, Mason TG, Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis. 2005;64:1068–70.

    Article  CAS  PubMed  Google Scholar 

  90. Belsky MR, Feldon P, Millender LH, Nalebuff EA, Phillips C. Hand involvement in psoriatic arthritis. J Hand Surg Am. 1982;7:203–7.

    Article  CAS  PubMed  Google Scholar 

  91. Malviya A, Johnson-Lynn S, Avery P, Deehan D, Foster H. Juvenile idiopathic arthritis in adulthood and orthopaedic intervention. Clin Rheumatol. 2009;28:1411–7.

    Article  PubMed  Google Scholar 

  92. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989–99.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Elana J. Bernstein and Lisa A. Mandl declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA

    Elana J. Bernstein & Lisa A. Mandl

Authors
  1. Elana J. Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa A. Mandl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa A. Mandl.

Additional information

This article is part of the Topical Collection on Surgery and Perioperative Care

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernstein, E.J., Mandl, L.A. Changing Incidence of Orthopedic Surgery in Rheumatic Disease: Contributing Factors. Curr Rheumatol Rep 15, 365 (2013). https://doi.org/10.1007/s11926-013-0365-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0365-8

Keywords

Search

Navigation